Antiviral drugs: pros and cons
Antiviral drugs: for and against the flu, and its constantly mutating species, have become the “plague” of our century. According to statistics, the incidence threshold does not exceed the epidemiological norm, but every year a huge number of people suffer from seasonal outbreaks of the disease. Modern pharmacology offers a wide range of antiviral agents. Doctors, when making a diagnosis of “flu” or “SARS”, are required to prescribe a drug of this pharmacological group. And now you are already in the pharmacy buying packs of “Arbidol”, “Ingavirin”, “Kagocel” and other advertised brands.
Pharmaceutical companies make a profit, and the patient does not even think about the fact that the antiviral effectiveness of these drugs is not proven. Translation of instructions and descriptions of the drug “Tamiflu” indicates that at the moment its effectiveness is almost 100% proven in the case of treatment of the type of flu “A”. Unlike other” players ” in the antiviral market.
Conducting research in a clinical setting costs fabulous money. A drug that has been on the market for 10 to 40 years cannot be considered safe, and side effects may occur later. The effectiveness of Immunostimulants is especially questionable, since the field of immunology is just beginning to develop, and, as a rule, such drugs have many contraindications.
Analogue treatment or prevention of influenza is vaccination. But most of the population is skeptical about vaccinations, fearing side effects and rejection of the vaccine by the immune system. There are such cases, but they are usually isolated. Many people confuse the pharmacological effects of vaccines – they are always aimed at preventing a specific strain. You will not get sick with the flu, other viral diseases – HPV, SARS or the common cold can break your body immediately after vaccination.
Vaccination in municipal clinical institutions is a free service. Translation of the latest research by the STIKO permanent vaccination Commission, which operates at the Robert Koch Institute (Berlin), proves that the risk group for influenza includes the elderly, infants, pregnant women, and health workers. German scientists draw attention to the fact that vaccination should be carried out annually, since flu strains mutate every season and become resistant to the existing vaccine.
Russian scientists from the NGO “Microgen” have already patented a new “smart split-vaccine” for influenza. Inoculation contains not only surface, but also internal antigens of influenza viruses. This technology makes it possible not to use excipients in the vaccine that increase the resistance of virus antibodies. The vaccine will be used everywhere from 2016. The producers plan to cover 40% of the domestic market of Russia and the West.